"&#xa0;\nWritten evidence submitted by AstraZeneca (AMR0018)&#xa0;Executive summary&#xa0;&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nAbout AstraZeneca&#xa0;\n&#xa0;Terms of Reference&#xa0;\nHow has antimicrobial resistance developed in the past decade?\n&#xa0;\n&#xa0;\n&#xa0;\nWhat are the gaps in our knowledge about antimicrobial resistance?\n&#xa0;\n&#xa0;\nIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nWhat measures (including behavioural change) \nhave been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nWhat global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nRecommendations for action&#xa0;\n&#xa0;\n&#xa0;&#xa0;&#xa0;\n&#xa0;&#xa0;\n&#xa0;\n&#xa0;November 2013\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;REFERENCES&#xa0;\n&#xa0;\n&#xa0;\nAnnual Report of the Chief Medical Officer Volume Two, 2011. Infections and the rise of antimicrobial resistance. Available at: \nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf\n. Accessed September 2013\n World Health Organization Regional Office for Europe. Self-prescription of antibiotics boosts superbugs epidemic in the European Region. November 16, 2012. Available at: \nhttp://www.euro.who.int/en/what-we-publish/information-for-the-media/sections/latest-press-releases/self-prescription-of-antibiotics-boosts-superbugs-epidemic-in-the-european-region\n. Accessed September 2013\n Office of Health Economics. New drugs to tackle antimicrobial resistance: analysis of EU policy options. April 2011. Available for download from: \nhttp://www.ohe.org/page/index.cfm\n. Accessed September, 2013\n Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating Antimicrobial Resistance: Policy Recommendations To Save Lives. Clin Infect Dis 2011:52(Suppl 5):S397-428\n Projan S. (2003) Why big pharma is getting out of AB discovery, Current Opinion in Microbiology 2003, 6:427-430\n Smith R and Coast J, The true cost of antimicrobial resistance, British Medical Journal 2013;346\nhttp://www.bmj.com/content/346/bmj.f1493\n \n Sally Davies, The drugs don’t work, Sunday Times, 15 September 2013\nhttp://www.thesundaytimes.co.uk/sto/newsreview/features/article1313446.ece\n \n Innovative\n Medicines Initiative, \n9th Call for Proposals 2013\n, July 2013. \nhttp://www.imi.europa.eu/webfm_send/914\n Health Protection Agency, Healthcare-Associated Infection and Antimicrobial Resistance: 2010-2011, August 2012 \nhttp://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912\n \n Department of Health, UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, 10 September 2013. Available at \nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf\n House of Commons Science and Technology Committee,  Uncorrected Transcript Of Oral Evidence from the Chief Medical Officer, Department of Health, HC 921-I, Published 11\nth\n February 2013\nhttp://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm\n \n World Health Organisation. World Health Day 2011: Urgent action necessary to safeguard drug treatments. News Release. 06 April 2011 \nhttp://www.who.int/mediacentre/news/releases/2011/whd_20110406/en/index.html\n World Economic Forum, Global Risks 2013: Eighth Edition. Published 2013. Available at \nhttp://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/\n Accessed September 2013\n Infectious Diseases Society of America, The 10 x 20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020, Clin Infect Dis. (2010) 50 (8): 1081-1083\nhttp://cid.oxfordjournals.org/content/50/8/1081.full.pdf+html\n \n Elaine A Irving presentation, New Drugs for Bad Bugs – Regulatory aspects in Innovative Medicines Initiative projects, November 2010\nhttp://www.efpia.eu/uploads/Modules/Documents/nd4bb_overview_jan_2013.pdf\n \n Pew Health Group, Fact sheet:  The Generating Antibiotic Incentives Now Act of 2011, 20 September 2011 \nhttp://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf\n BBC News Online, Antibiotics resistance 'as big a risk as terrorism' - medical chief, 11 March 2013\nhttp://www.bbc.co.uk/news/health-21737844\n"